1. Home
  2. AIMD vs BRTX Comparison

AIMD vs BRTX Comparison

Compare AIMD & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIMD

Ainos Inc.

HOLD

Current Price

$1.91

Market Cap

10.2M

Sector

Health Care

ML Signal

HOLD

Logo BioRestorative Therapies Inc. (NV)

BRTX

BioRestorative Therapies Inc. (NV)

HOLD

Current Price

$1.04

Market Cap

9.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIMD
BRTX
Founded
1984
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Managed Health Care
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2M
9.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AIMD
BRTX
Price
$1.91
$1.04
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.9M
22.3K
Earning Date
03-06-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$113,037.00
$383,400.00
Revenue This Year
N/A
$112.14
Revenue Next Year
N/A
$139.81
P/E Ratio
N/A
N/A
Revenue Growth
178.19
1.70
52 Week Low
$1.61
$0.98
52 Week High
$4.50
$2.50

Technical Indicators

Market Signals
Indicator
AIMD
BRTX
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
AIMD
BRTX

About AIMD Ainos Inc.

Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.

About BRTX BioRestorative Therapies Inc. (NV)

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

Share on Social Networks: